Fukaya Mototsugu, Sato Kenji, Yamada Takahiro, Sato Mitsuko, Fujisawa Shigeki, Minaguchi Satoko, Kimata Hajime, Dozono Haruhiko
Tsurumai Kouen Clinic, Nagoya.
Department of Dermatology, Hannan Chuo Hospital.
Clin Cosmet Investig Dermatol. 2016 Jul 4;9:151-8. doi: 10.2147/CCID.S109946. eCollection 2016.
Topical corticosteroids (TCS) are regarded as the mainstay treatment for atopic dermatitis (AD). As AD has a tendency to heal naturally, the long-term efficacy of TCS in AD management should be compared with the outcomes seen in patients with AD not using TCS. However, there are few long-term studies that consider patients with AD not using TCS. We designed a prospective multicenter cohort study to assess the clinical outcomes in patients with AD who did not use TCS for 6 months and then compared our results with an earlier study by Furue et al which considered AD patients using TCS over 6 months. Our patients' clinical improvement was comparable with the patients described in Furue's research. In light of this, it is reasonable for physicians to manage AD patients who decline TCS, as the expected long-term prognosis is similar whether they use TCS or not.
外用糖皮质激素(TCS)被视为特应性皮炎(AD)的主要治疗方法。由于AD有自然愈合的倾向,TCS在AD治疗中的长期疗效应与未使用TCS的AD患者的结局进行比较。然而,很少有长期研究关注未使用TCS的AD患者。我们设计了一项前瞻性多中心队列研究,以评估未使用TCS达6个月的AD患者的临床结局,然后将我们的结果与古江等人早期的一项研究进行比较,该研究考虑了使用TCS超过6个月的AD患者。我们患者的临床改善情况与古江研究中描述的患者相当。鉴于此,对于拒绝使用TCS的AD患者,医生进行相应处理是合理的,因为无论是否使用TCS,预期的长期预后相似。